SCHEMBL4058397

SCHEMBL4058397

CO[Si](CCN1CCNCC1)(OC)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.40
CXCR4 P61073 2/20 0.39
CYP1A2 P05177 1/20 0.37
CHRM2 P08172 1/20 0.37
SLC6A4 P31645 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
PIM1 P11309 1/20 0.36
APOBEC3A P31941 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
HTR4 Q13639 2/20 0.35
ALDH1A1 P00352 1/20 0.35
SIGMAR1 Q99720 2/20 0.34
RAD52 P43351 1/20 0.34
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL465021 0.88 CXCR4 (0.46) MEN1KMT2APOLBSMN1; SMN2HSD17B10
SCHEMBL4067459 0.86 CXCR4 (0.47) MEN1KMT2APOLBSMN1; SMN2HSD17B10
SCHEMBL17457448 0.86 CXCR4 (0.48) MEN1KMT2APOLBSMN1; SMN2HSD17B10
SCHEMBL4061521 0.82 MEN1 (0.41) MEN1KMT2APOLBSMN1; SMN2HSD17B10
SCHEMBL4069690 0.82 MEN1 (0.41) MEN1KMT2APOLBSMN1; SMN2HSD17B10
SCHEMBL12581088 0.80 HRH3 (0.37) MEN1KMT2APOLBCYP1A2ALDH1A1
SCHEMBL12802639 0.80 HRH3 (0.41) MEN1KMT2APOLBCYP1A2ALDH1A1
SCHEMBL4061260 0.80 POLB (0.38) MEN1KMT2APOLBSMN1; SMN2HSD17B10
SCHEMBL31687727 0.80 CXCR4 (0.42) MEN1KMT2APOLBSMN1; SMN2HSD17B10
SCHEMBL31687750 0.80 CXCR4 (0.42) MEN1KMT2APOLBSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569691-B2 Protected piperazino group-bearing organoxysilane compound and making method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-08-04 US claimed
US-7569691-B2 Protected piperazino group-bearing organoxysilane compound and making method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-08-04 US disclosed
CN-101356215-A Thermoplastic elastomer composition, foam product, and process for production of the composition or foam product JSR CORP (JP) 2009-01-28 CN disclosed
EP-1714968-B1 Protected piperazino group-bearing organoxysilane compound and making method SHINETSU CHEMICAL CO (JP) 2008-07-16 EP disclosed
US-20060241294-A1 Protected piperazino group-bearing organoxysilane compound and making method SHIN-ETSU CHEMICAL CO., LTD. 2006-10-26 US disclosed
EP-1714968-A1 Protected piperazino group-bearing organoxysilane compound and making method Shin-Etsu Chemical Co., Ltd. (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241294-A1 Protected piperazino group-bearing organoxysilane compound and making method PIEZO1, VCL, VIM MEN1 4010/4885KMT2A 173/4885POLB 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.